CN100398106C - Nk-1受体拮抗剂对抗良性前列腺增生的用途 - Google Patents

Nk-1受体拮抗剂对抗良性前列腺增生的用途 Download PDF

Info

Publication number
CN100398106C
CN100398106C CNB028087305A CN02808730A CN100398106C CN 100398106 C CN100398106 C CN 100398106C CN B028087305 A CNB028087305 A CN B028087305A CN 02808730 A CN02808730 A CN 02808730A CN 100398106 C CN100398106 C CN 100398106C
Authority
CN
China
Prior art keywords
methyl
phenyl
trifluoromethyl
tolyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028087305A
Other languages
English (en)
Chinese (zh)
Other versions
CN1503684A (zh
Inventor
S·布塞尔
A·P·D·W·福特
T·霍夫曼
B·伦茨
A·J·斯莱特
P·万肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1503684A publication Critical patent/CN1503684A/zh
Application granted granted Critical
Publication of CN100398106C publication Critical patent/CN100398106C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028087305A 2001-04-23 2002-02-02 Nk-1受体拮抗剂对抗良性前列腺增生的用途 Expired - Lifetime CN100398106C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23
EP01109853.0 2001-04-23

Publications (2)

Publication Number Publication Date
CN1503684A CN1503684A (zh) 2004-06-09
CN100398106C true CN100398106C (zh) 2008-07-02

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028087305A Expired - Lifetime CN100398106C (zh) 2001-04-23 2002-02-02 Nk-1受体拮抗剂对抗良性前列腺增生的用途

Country Status (17)

Country Link
US (1) US20030004157A1 (enExample)
EP (1) EP1385577B1 (enExample)
JP (1) JP4146730B2 (enExample)
KR (1) KR100599134B1 (enExample)
CN (1) CN100398106C (enExample)
AR (1) AR035935A1 (enExample)
AT (1) ATE323531T1 (enExample)
AU (1) AU2002250876B2 (enExample)
BR (1) BR0209151A (enExample)
CA (1) CA2444395C (enExample)
DE (1) DE60210760T2 (enExample)
DK (1) DK1385577T3 (enExample)
ES (1) ES2261657T3 (enExample)
MX (1) MXPA03009720A (enExample)
PT (1) PT1385577E (enExample)
WO (1) WO2002085458A2 (enExample)
ZA (1) ZA200308110B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
WO2004067007A1 (en) * 2003-01-31 2004-08-12 F. Hoffmann-La Roche Ag NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
JP4490421B2 (ja) * 2003-07-03 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルｎｋ１／ｎｋ３アンタゴニスト
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
EP2281556A1 (en) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablets with improved drugs substance dispersibility
DK2774925T3 (en) 2005-11-08 2017-02-27 Vertex Pharma Heterocyclic modulators of ATP binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CN103626744B (zh) 2007-12-07 2016-05-11 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
AU2008335440B2 (en) 2007-12-07 2013-11-07 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
KR20110136813A (ko) 2009-03-17 2011-12-21 다이이찌 산쿄 가부시키가이샤 아미드 유도체
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
EP2555755B2 (en) 2010-04-07 2019-07-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
RU2673084C2 (ru) 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
DK3221692T3 (da) 2014-11-18 2021-08-23 Vertex Pharma Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
WO2019148246A1 (en) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Parenteral formulations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656639A (en) * 1995-01-30 1997-08-12 Sanofi Heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present
CN1265652A (zh) * 1997-08-06 2000-09-06 伊莱利利公司 用作速激肽受体拮抗剂的2－酰基氨基丙胺化合物
CN1270959A (zh) * 1999-02-24 2000-10-25 弗·哈夫曼-拉罗切有限公司 4－苯基－吡啶衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
ID24468A (id) * 1997-08-06 2000-07-20 Lilly Co Eli 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
RS50932B (sr) * 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656639A (en) * 1995-01-30 1997-08-12 Sanofi Heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present
US5859029A (en) * 1995-01-30 1999-01-12 Sanofi Heterocyclic compounds method of preparing them and pharmeutical compositions in which they are present
CN1265652A (zh) * 1997-08-06 2000-09-06 伊莱利利公司 用作速激肽受体拮抗剂的2－酰基氨基丙胺化合物
CN1270959A (zh) * 1999-02-24 2000-10-25 弗·哈夫曼-拉罗切有限公司 4－苯基－吡啶衍生物

Also Published As

Publication number Publication date
JP2004529931A (ja) 2004-09-30
ES2261657T3 (es) 2006-11-16
AU2002250876B2 (en) 2005-03-03
EP1385577A2 (en) 2004-02-04
ZA200308110B (en) 2005-03-30
ATE323531T1 (de) 2006-05-15
CA2444395C (en) 2010-12-21
PT1385577E (pt) 2006-08-31
CN1503684A (zh) 2004-06-09
WO2002085458A3 (en) 2003-10-30
WO2002085458A2 (en) 2002-10-31
BR0209151A (pt) 2004-07-13
EP1385577B1 (en) 2006-04-19
KR100599134B1 (ko) 2006-07-12
DE60210760D1 (de) 2006-05-24
US20030004157A1 (en) 2003-01-02
CA2444395A1 (en) 2002-10-31
JP4146730B2 (ja) 2008-09-10
AR035935A1 (es) 2004-07-28
DK1385577T3 (da) 2006-08-21
KR20040007503A (ko) 2004-01-24
MXPA03009720A (es) 2004-01-29
DE60210760T2 (de) 2006-11-23

Similar Documents

Publication Publication Date Title
CN100398106C (zh) Nk-1受体拮抗剂对抗良性前列腺增生的用途
AU2002250876A1 (en) Use of NK-1 receptor antagonists against benign prostatic hyperplasia
CN107108576B (zh) 作为血浆激肽释放酶抑制剂的n-((杂)芳基甲基)-杂芳基-甲酰胺化合物
CN105324117B (zh) 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物
TWI675832B (zh) 新穎的酶抑制劑
JP7688078B2 (ja) 遺伝性血管性浮腫の治療
JP6762312B2 (ja) 過剰な体脂肪の治療処置または美容処置のためのｎｋ−３受容体拮抗薬
HUP0401210A2 (hu) NK-1 receptor antagonisták felhasználása agy-, gerinc- vagy idegsérülések kezelésére alkalmas gyógyászati készítmények előállítására
US20140187563A1 (en) Combination therapy in treatment of oncological and fibrotic diseases
JP2009504656A (ja) デアセチラーゼ阻害剤の使用法
US20240360166A1 (en) Salts and solid forms of a compound having glp-1 agonist activity
CN102227227A (zh) 包含吡啶并[4，3-d]嘧啶衍生的HSP90抑制剂和HER2抑制剂的药物组合
CN104788423B (zh) 一种新的囊性纤维化跨膜传导调节因子抑制剂
EP1430894A1 (en) Lymphocytic activation inhibitor and remedial agent for autoimmune disease
KR20060130619A (ko) 유기 화합물의 조합물
EP1433479A1 (en) Appetite-stimulating agents and remedies for anorexia
HK40101443A (en) Treatments of hereditary angioedema
HK40070596A (en) Treatments of hereditary angioedema
BR122020026459B1 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática, seus usos, e composição farmacêutica
MXPA06008295A (en) Combination of organic compounds
WO2010099388A1 (en) Combinational use of a pde3 inhibitor and other agents
AU2009209152A1 (en) A method of administering a PDE3 inhibitor via titration for the treatment of peripheral arterial disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20080702